文献速递白血病

USP22 调控 KMT2Ar 急性白血病中 MEIS1 蛋白丰度与基因转录

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.
PubMed 文献 · Blood · 2026-01-01

该研究在 KMT2Ar B 细胞急性淋巴细胞白血病细胞系中进行全基因组 CRISPR/Cas9 筛选,鉴定出去泛素化酶 USP22 为 MEIS1 蛋白稳定性的新调控因子。USP22 与 MEIS1 在关键致癌靶基因上协同结合,保护 MEIS1 免受蛋白酶体降解。遗传或化学抑制 USP22 导致 MEIS1 多泛素化并降解,下调靶基因表达,提示 USP22 可作为 KMT2Ar 白血病的潜在治疗靶点。

要点

  • USP22 是 KMT2Ar 急性白血病中 MEIS1 蛋白稳定性的新调控因子。
  • USP22 与 MEIS1 协同结合致癌靶基因,保护 MEIS1 免受蛋白酶体降解。
  • 抑制 USP22 可导致 MEIS1 降解并下调靶基因,是潜在治疗靶点。

核心结论

  • USP22 是调控 MEIS1 蛋白稳定性的新因子,可能成为 KMT2Ar 白血病的治疗靶点。

研究设计与样本

  • 在 KMT2Ar B 细胞急性淋巴细胞白血病细胞系中进行全基因组 CRISPR/Cas9 筛选。

主要发现

  • USP22 被鉴定为 MEIS1 蛋白稳定性的新调控因子。
  • USP22 遗传缺失损害 KMT2Ar 急性白血病模型的细胞生长和增殖。
  • 染色质免疫沉淀显示 USP22 与 MEIS1 在关键致癌靶基因上协同结合。
  • 遗传或化学抑制 USP22 导致 MEIS1 多泛素化、蛋白酶体降解及靶基因表达下调。

临床怎么用

  • USP22 抑制可能作为 KMT2Ar 急性白血病(包括对 menin 抑制剂耐药者)的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute leukemias harboring translocations involving gene lysine methyltransferase 2A (KMT2A) have a poor prognosis due to chemotherapy resistance with rapid relapse following standard treatments. The resulting KMT2A fusion proteins dysregulate gene expression, leading to an upregulation of leukemogenic transcription factors such as HOXA9 and MEIS1, which drives leukemic transformation. Although menin inhibitors are proving to be promising new therapeutics for patients with KMT2A-rearranged (KMT2Ar) acute leukemia, resistance mechanisms have already been described and new therapeutic approaches for this patient subgroup must be identified. Here, a genome-wide CRISPR/Cas9 screen in a KMT2Ar B-cell acute lymphoblastic leukemia cell line identified the deubiquitinase ubiquitin-specific peptidase 22 (USP22) as a novel regulator of MEIS1 protein stability. USP22 is a member of the Spt-Ada-Gcn5 acetyltransferase multiprotein complex, which has crucial functions in shaping the chromatin landscape and modulating transcription. Genetic depletion of USP22 impaired cellular growth and proliferation in KMT2Ar acute leukemia models. Chromatin immunoprecipitation revealed cooperative binding between USP22 and MEIS1 at critical oncogenic target genes, suggesting that USP22 safeguards leukemogenic transcription by protecting MEIS1 from proteasomal degradation. Genetic or chemical inhibition of USP22 led to the polyubiquitination of MEIS1, resulting in proteasomal degradation and downregulation of the expression of target genes. Our study identifies USP22 as a novel regulator of MEIS1 protein stability that could potentially be exploited as a therapeutic target in the future in KMT2Ar leukemias.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bröchtel S, Schneider C, Müller M, et al. USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia. Blood. 2026. PMID: 42418681. doi:10.1182/blood.2025031845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。